Stock Traders Buy Large Volume of BioVie Call Options (NASDAQ:BIVI)

BioVie Inc. (NASDAQ:BIVI) saw unusually large options trading on Monday. Traders acquired 2,043 call options on the stock. This represents an increase of approximately 2,661% compared to the average daily volume of 74 call options.

Institutional Trading of BioVie

A hedge fund recently bought a new stake in BioVie stock. CVI Holdings LLC purchased a new position in shares of BioVie Inc. (NASDAQ:BIVI) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 599,897 shares of the company’s stock, valued at approximately $317,000. CVI Holdings LLC owned 1.50% of BioVie as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 4.59% of the company’s stock.

BioVie Stock Up 166.0 %

NASDAQ:BIVI traded up $3.90 during trading hours on Monday, hitting $6.25. 66,353,820 shares of the company’s stock traded hands, compared to its average volume of 740,655. BioVie has a 52 week low of $1.04 and a 52 week high of $58.20. The business’s fifty day simple moving average is $2.25 and its two-hundred day simple moving average is $1.14. The firm has a market cap of $382.29 million, a P/E ratio of -2.50 and a beta of 0.67.

BioVie (NASDAQ:BIVI) last issued its quarterly earnings data on Monday, September 30th. The company reported ($6.60) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, ThinkEquity started coverage on shares of BioVie in a research report on Monday, July 1st. They set a “buy” rating and a $3.00 target price for the company.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.